Biochemistry & Physiology: Open Access
Open Access

Proteins are essential biomolecules that carry out virtually every function within living organisms, from catalyzing biochemical reactions to providing structural support. For a protein to function correctly, it must fold into a specific three-dimensional structure that is determined by its amino acid sequence. Protein folding is a highly regulated and dynamic process, with polypeptides navigating through various intermediate conformations before reaching their native functional state. This process is assisted by molecular chaperones, which help prevent misfolding and assist in the proper folding of nascent proteins. However, when folding is disrupted due to genetic mutations, cellular stress, or environmental factors, proteins may adopt incorrect conformations, leading to misfolding. Misfolded proteins often fail to perform their intended functions and may aggregate, forming toxic oligomers and fibrils [1]. These aggregates are central to the pathogenesis of several diseases, including Alzheimer's disease, Parkinson's disease, and Huntington's disease, collectively known as protein misfolding diseases. The accumulation of misfolded proteins can overwhelm the cellular quality control systems, leading to cellular dysfunction and tissue damage. Recent research has made significant strides in understanding the molecular mechanisms that drive protein folding and the consequences of misfolding. These advances have implications for therapeutic strategies aimed at preventing or reversing misfolding, such as the development of small molecules that promote correct folding or inhibit aggregation. Furthermore, gene therapies designed to correct genetic mutations responsible for misfolding are being explored as potential treatments for these debilitating diseases. This review aims to provide an overview of protein folding mechanisms, the role of molecular chaperones, and the pathological consequences of protein misfolding, with a focus on their relevance to human diseases and therapeutic strategies [2].

Methods

To characterize protein folding mechanisms and the implications of misfolding, a systematic review of the literature was conducted using databases such as PubMed, Scopus, and Google Scholar. Studies published in the last 10 years were included, focusing on the biochemical processes and pathways involved in protein folding and misfolding. Keywords such as “protein folding,” “misfolding diseases,” “chaperones,” “protein aggregation,” and “neurodegenerative diseases” were used to identify relevant articles. Articles that provided insights into the role of molecular chaperones, folding intermediates, and the cellular machinery involved in protein quality control were prioritized. Studies on the molecular and structural aspects of misfolded proteins, including the formation of aggregates and their association with disease, were also reviewed. Additionally, research on therapeutic approaches, including small molecules, gene therapies, and chaperone-based interventions, was incorporated to evaluate potential strategies for treating protein misfolding diseases. Data from both in vitro and in vivo studies were analyzed to provide a comprehensive understanding of protein folding mechanisms and their disruption in disease [3]. Statistical analyses were performed when applicable, and key findings were synthesized to present a unified perspective on the topic.

Results

The reviewed studies revealed that protein folding is a highly complex and dynamic process that is influenced by various intrinsic and extrinsic factors. The process begins as a polypeptide chain emerges from the ribosome, folding into its native structure assisted by molecular chaperones, such as Hsp70, Hsp90, and chaperonins. These chaperones prevent incorrect folding by stabilizing intermediate states and facilitating the proper folding pathway. When folding is disrupted, proteins can adopt non-native conformations that are often prone to aggregation. Misfolded proteins may undergo partial refolding, but if these attempts fail, they are typically targeted for degradation by the proteasome or autophagy [4]. However, when these quality control systems become overwhelmed, misfolded proteins aggregate, forming toxic species that are associated with the pathogenesis of diseases such as Alzheimer's, Parkinson's, and cystic fibrosis. Studies on amyloid-beta and tau aggregation in Alzheimer's disease, alpha-synuclein in Parkinson's disease, and mutant CFTR in cystic fibrosis have provided valuable insights into how misfolded proteins accumulate and cause cellular damage. In vitro experiments have shown that small molecules, such as chemical chaperones and aggregation inhibitors, can promote protein folding and prevent aggregation in model systems. Moreover, gene therapies aimed at correcting the underlying genetic mutations responsible for misfolding have shown promise in preclinical studies. These results emphasize the importance of targeting protein folding pathways and the aggregation process in developing therapeutic strategies for protein misfolding diseases [5].

Discussion

Protein misfolding diseases are a diverse group of disorders that share the common feature of protein aggregation. The pathological aggregation of misfolded proteins, such as amyloid plaques in Alzheimer's disease or Lewy bodies in Parkinson's disease, plays a central role in disease progression. The mechanisms underlying protein folding and misfolding are still not fully understood, but several key insights have emerged. Molecular chaperones are essential in guiding the folding process, and their dysfunction can lead to protein misfolding and aggregation [6]. In addition, cellular quality control systems, including the proteasome and autophagy, are critical for maintaining protein homeostasis (proteostasis). When these systems are overwhelmed or impaired, misfolded proteins accumulate and form toxic aggregates, which in turn disrupt cellular function and contribute to disease pathology [7]. The therapeutic potential of targeting protein folding and aggregation is a promising area of research. Small molecules that promote correct folding, inhibit aggregation, or enhance protein degradation pathways are being developed as potential treatments. Moreover, gene therapies aimed at correcting mutations in misfolded proteins, such as in cystic fibrosis or sickle cell disease, have shown promise in early-stage clinical trials. Despite these advances, challenges remain in the development of effective therapies. The heterogeneity of misfolded protein diseases, the complex nature of protein aggregation, and the risk of off-target effects complicate the treatment landscape. Nevertheless, continued research into the molecular mechanisms of protein folding, misfolding, and aggregation, along with the development of innovative therapeutic approaches, offers hope for improving outcomes for patients suffering from these debilitating diseases [8-10].

Conclusion

Protein folding is a critical process that ensures the proper function of cellular proteins. Disruptions in protein folding can lead to the accumulation of misfolded proteins, which form toxic aggregates and are implicated in a range of protein misfolding diseases, including Alzheimer's, Parkinson's, and cystic fibrosis. Molecular chaperones and quality control systems play vital roles in ensuring the correct folding and maintenance of proteins, and their dysfunction contributes to disease progression. The study of protein folding mechanisms has provided valuable insights into the causes of misfolding and aggregation, opening new avenues for therapeutic interventions. Small molecules that promote proper folding, inhibit aggregation, or enhance protein degradation hold potential for treating these diseases. Additionally, gene therapies that target the underlying genetic causes of protein misfolding are being explored. Despite significant progress, challenges such as protein heterogeneity and the complexity of aggregation remain, and more research is needed to develop safe and effective therapies. Ultimately, understanding the molecular mechanisms of protein folding and misfolding will be key to developing treatments that can alleviate or prevent the progression of these devastating diseases.

Acknowledgement

None

Conflict of Interest

None

References

1. La Fata G (2015)Vitamin E Supplementation Delays Cellular Senescence In Vitro. Biomed Res Int 2015: 563-247.

Indexed at, Google Scholar, Crossref

2. Butt H (2017)Protective role of vitamin E preconditioning of human dermal fibroblasts against thermal stress in vitro. Life Sci 184: 1-9.

Indexed at, Google Scholar, Crossref

3. Liu J (2017)Na/K-ATPase Signaling and Salt Sensitivity: The Role of Oxidative Stress. Antioxidants Basel 6: 1-3.

Indexed at, Google Scholar, Crossref

4. Foyouzi (2004)Effects of oxidants and antioxidants on proliferation of endometrial stromal cells. Fertil Steril 3: 1019-1022.

Indexed at, Google Scholar, Crossref

5. Zeng JP (2014) Repeated exposure of mouse dermal fibroblasts at a sub-cytotoxic dose of UVB leads to premature senescence: a robust model of cellular photoaging. J Dermatol Sci 73: 49-56.

Indexed at, Google Scholar, Crossref

6. Alcendor RR (2007)Sirt1 regulates aging and resistance to oxidative stress in the heart. Circ Res 100(10): 1512-21.

Indexed at, Google Scholar, Crossref

7. Van Deursen JM (2014)The role of senescent cells in ageing. Nature 509: 439-446.

Indexed at, Google Scholar, Crossref

8. Acosta JC (2013)A complex secretory program orchestrated by the inflammasome controls paracrine senescence. Nat Cell Biol 15: 978-990.

Indexed at, Google Scholar, Crossref

9. Nelson G (2012)A senescent cell bystander effect: senescence-induced senescence. Aging Cell 11: 345-349.

Indexed at, Google Scholar, Crossref

10. Petropoulou C (2001)Clusterin/apolipoprotein J is a novel biomarker of cellular senescence that does not affect the proliferative capacity of human diploid fibroblasts. FEBS Lett 509: 287-297.

Indexed at, Google Scholar, Crossref